Amarin (AMRN) NCE Delay Could Be Related to Patents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Reiterates a 'Buy' on Amarin Corporation (AMRN); Positive View on Vascepa
September 11, 2012 8:18 AM EDTCanaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $26.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target; maintain positive view on Vascepa approval and commercial, partnering potential. We continue to expect BD talks to intensify and Vascepa to... More
Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again
September 11, 2012 8:15 AM EDTShares of Amarin Corp Plc (Nasdaq: AMRN) are getting hit Tuesday morning following a late-Monday disclosure for Vascepa.
According to the filing, Amarin... More
Amarin (AMRN) Said No FDA NCE Decision in August Orange Book
September 10, 2012 5:10 PM EDTAmarin Corp Plc (NASDAQ: AMRN) said after the close of trading Monday that it does not expect an FDA NCE decision by the next Orange Book, due on our about September 14, 2012.
From the filing:
Typically, the U.S. Food and Drug Administration (FDA) publishes a determination on the... More
